FDA News

FDA grants priority review to Opdivo for small cell lung cancer

April 19, 2018
The FDA granted priority review designation to nivolumab for the treatment of patients with small cell lung cancer whose disease progressed after two…
Meeting News

Neoadjuvant pembrolizumab appears effective for resectable melanoma

April 18, 2018
Neoadjuvant pembrolizumab followed by curative-intent resection and adjuvant therapy conferred 1-year recurrence-free survival of 55% among patients…
Meeting News

Biomarkers predict response to pembrolizumab in head and neck squamous cell carcinoma

April 18, 2018
CHICAGO — PD-L1 expression and T-cell activated gene expression profile independently predicted response, PFS and OS among a cohort of patients…
Meeting NewsPerspective

Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

April 17, 2018
The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with…
Meeting News

Dual IDO1, PD-L1 inhibition safe for advanced solid tumors

April 17, 2018
The addition of the highly selective IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab appeared safe for patients with advanced solid…
Meeting News

Pembrolizumab prolongs survival in recurrent, metastatic head and neck squamous cell carcinoma

April 17, 2018
CHICAGO — Pembrolizumab extended OS compared with standard chemotherapy for patients with relapsed or metastatic head and neck squamous cell…
Feature

Study designed to assess side effects of immunotherapy for non-small cell lung cancer

April 17, 2018
The Lung Cancer Registry has launched a study designed to assess the side effects associated with use of immune checkpoint inhibitors for the…
Meeting News

Durvalumab-tremelimumab combination shows antitumor activity in urothelial cancer

April 17, 2018
The combination of durvalumab and tremelimumab demonstrated antitumor activity among patients with urothelial cancer, according to study results…
Meeting News

Nivolumab confers significant OS benefit in recurrent or metastatic head and neck squamous cell carcinoma

April 16, 2018
CHICAGO — Nivolumab continued to confer a significant OS benefit compared with investigator’s choice of therapy among patients with…
Meeting NewsPerspective

Atezolizumab plus chemotherapy improves PFS in non-small cell lung cancer

April 16, 2018
CHICAGO — The addition of atezolizumab to bevacizumab plus chemotherapy extended PFS for patients with non-small cell lung cancer, according to…